Department of Histopathology, King Edward Memorial Hospital, Perth, Western Australia, Australia; School for Women's and Infants' Health, University of Western Australia, Crawley, Australia.
Hum Pathol. 2013 Dec;44(12):2774-81. doi: 10.1016/j.humpath.2013.07.028. Epub 2013 Oct 14.
Most ovarian sex cord-stromal tumors (SCSTs) can be categorized on the basis of conventional histology, but approximately 10% of cases are unclassified because they present indeterminate or overlapping morphologic features. Immunohistochemical and molecular studies of unclassified ovarian SCST are very limited, but recently, it has been demonstrated that 2 major subgroups of SCST, adult-type granulosa cell tumor and Sertoli-Leydig cell tumor, are characterized by somatic mutations in FOXL2 and DICER1, respectively. In this study, 12 diagnostically problematic ovarian SCST, including 9 unclassified tumors, were investigated for FOXL2 and DICER1 mutations and for immunohistochemical expression of calretinin, CD56, CD99, estrogen receptor α, estrogen receptor β, FOXL2, inhibin, progesterone receptor, and steroidogenic factor-1. Four of 11 tumors with satisfactory analysis showed a FOXL2 mutation; 3 of these cases were reported initially as unclassified SCST and 1 as Sertoli-Leydig cell tumor. Conversely, 3 cases with an original diagnosis of granulosa cell tumor were FOXL2 mutation-negative, and none of 7 tumors with satisfactory analysis demonstrated a DICER1 mutation. All tumors expressed at least 4 of the immunomarkers examined, although staining was often focal and there was no consistent correlation with tumor morphology. In conclusion, molecular analysis is useful in the assessment of diagnostically challenging ovarian SCST. The absence of FOXL2 and DICER1 mutations in most unclassified SCST suggests that these could represent a distinct tumor subgroup with different molecular pathogenesis. Immunohistochemical profiles overlap with those of better categorized SCST, but staining may be focal or negative emphasizing the requirement for antibody panels in diagnostic assessment.
大多数卵巢性索-间质肿瘤(SCST)可基于常规组织学进行分类,但约 10%的病例无法分类,因为它们具有不确定或重叠的形态特征。未分类的卵巢 SCST 的免疫组织化学和分子研究非常有限,但最近已经证明,2 个主要的 SCST 亚组,成人型颗粒细胞瘤和 Sertoli-Leydig 细胞瘤,分别以 FOXL2 和 DICER1 的体细胞突变为特征。在这项研究中,对 12 例具有诊断问题的卵巢 SCST,包括 9 例未分类肿瘤,进行了 FOXL2 和 DICER1 突变以及 calretinin、CD56、CD99、雌激素受体 α、雌激素受体 β、FOXL2、抑制素、孕激素受体和类固醇生成因子-1 的免疫组织化学表达分析。在 11 例具有满意分析结果的肿瘤中,有 4 例显示 FOXL2 突变;其中 3 例最初报告为未分类的 SCST,1 例为 Sertoli-Leydig 细胞瘤。相反,3 例原始诊断为颗粒细胞瘤的病例 FOXL2 突变阴性,7 例具有满意分析结果的肿瘤均未显示 DICER1 突变。所有肿瘤均至少表达了 4 种检查的免疫标志物,尽管染色通常为局灶性,且与肿瘤形态无一致相关性。总之,分子分析对诊断具有挑战性的卵巢 SCST 的评估是有用的。大多数未分类的 SCST 中缺乏 FOXL2 和 DICER1 突变提示,这些可能代表具有不同分子发病机制的一个独特肿瘤亚组。免疫组织化学谱与分类较好的 SCST 重叠,但染色可能是局灶性或阴性,强调在诊断评估中需要抗体谱。